NR4A1 and breast cancer: In conclusion, this large population-based study did not demonstrate any benefit in OS from an early start of adjuvant chemotherapy among Danish breast cancer patients treated within 3 months of definitive surgery, or for any subgroups with potentially fast growing tumours according to increasing number of involved axillary lymph nodes, increasing malignancy grade or negative hormone receptor status.